WO2001011044A1 - Tumor antigen - Google Patents
Tumor antigen Download PDFInfo
- Publication number
- WO2001011044A1 WO2001011044A1 PCT/JP2000/005220 JP0005220W WO0111044A1 WO 2001011044 A1 WO2001011044 A1 WO 2001011044A1 JP 0005220 W JP0005220 W JP 0005220W WO 0111044 A1 WO0111044 A1 WO 0111044A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- peptide
- cells
- hla
- ctl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 128
- 239000000427 antigen Substances 0.000 title abstract description 58
- 108091007433 antigens Proteins 0.000 title abstract description 57
- 102000036639 antigens Human genes 0.000 title abstract description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 260
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 46
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 40
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 40
- 239000002157 polynucleotide Substances 0.000 claims abstract description 40
- 230000001939 inductive effect Effects 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000013598 vector Substances 0.000 claims abstract description 19
- 230000000295 complement effect Effects 0.000 claims abstract description 14
- 238000012216 screening Methods 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 95
- 201000011510 cancer Diseases 0.000 claims description 52
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229940022399 cancer vaccine Drugs 0.000 claims description 8
- 238000009566 cancer vaccine Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 abstract description 29
- 230000003213 activating effect Effects 0.000 abstract description 19
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract description 12
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract description 12
- 230000003993 interaction Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 107
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 67
- 101150028321 Lck gene Proteins 0.000 description 63
- 206010009944 Colon cancer Diseases 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 39
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 32
- 210000004881 tumor cell Anatomy 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 230000006698 induction Effects 0.000 description 18
- 230000027455 binding Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 108010047761 Interferon-alpha Proteins 0.000 description 14
- 102000006992 Interferon-alpha Human genes 0.000 description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 description 14
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 10
- 201000004101 esophageal cancer Diseases 0.000 description 10
- 230000011488 interferon-alpha production Effects 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 101150076615 ck gene Proteins 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 description 7
- 102000011786 HLA-A Antigens Human genes 0.000 description 6
- 108010075704 HLA-A Antigens Proteins 0.000 description 6
- 108010047620 Phytohemagglutinins Proteins 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000001885 phytohemagglutinin Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000001400 expression cloning Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000013332 literature search Methods 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101100355949 Caenorhabditis elegans spr-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 101150002258 HDR1 gene Proteins 0.000 description 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 241000179216 Lychnis ringspot virus Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 101710116850 Molybdenum cofactor sulfurase 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000997616 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 1 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to a novel tumor antigen, and more particularly, to a peptide having recognition by tumor-specific cytotoxic T cells, a polynucleotide encoding the peptide or a complementary strand thereof, and containing the polynucleotide.
- Vector, transformant containing recombinant vector, method for producing peptide, antibody against peptide, compound interacting therewith, method for screening the same, pharmaceutical composition using these, and use of these It relates to analysis means for diagnosis.
- cytotoxic T cells Cytotoxic TLymphocyte: hereinafter sometimes abbreviated as CTL
- CTL cytotoxic T cells
- Tumor antigens generated in tumor cells are degraded in the cells into peptides consisting of 8 to 11 amino acids (tumor antigen peptides), and human leukocyte antigen (Huma n Leuko), a major histocompatibility antigen.
- HLA human leukocyte antigen
- HLA is a cell membrane antigen and is expressed on almost all nucleated cells. HLA is roughly classified into class I antigen and class II antigen, and HLA recognized by cytotoxic T cells together with antigenic peptide is a class I antigen. HLA class I antigens are further classified into HLA-A, B, C, etc., and it has been reported that polymorphism exists in their genes.
- HLA—A24 allele (allele) It is found in about 60% of the population (many 95% of which have the genotype A2402), 20% of Caucasians and 12% of Africans. The HL A—A 2 allele is found in approximately 40% of Japanese, 53% of Chinese, 49% of Northern Casas, 38% of Southern Casas, and 23% of Black Africans .
- tumor antigen peptide capable of binding to HLA has a regularity (motif) in its sequence for each HLA type (typ). Cytotoxic T cells recognize this complex of tumor antigen peptide and HLA and damage tumor cells.
- tumor antigen refers to a protein or peptide possessed by tumor cells that can induce tumor-specific cytotoxic T cells.
- a tumor antigen peptide is a peptide produced by decomposing the tumor antigen in tumor cells, and induces tumor-specific cytotoxic T cells by binding to HLA molecules and presenting on the cell surface. It means a peptide that can be activated.
- tumor antigen ebitope tumor antigen determinant
- melanoma-specific tumor antigens include MART-1 / me 1 anA, gp100, and tyrosinase, which are also present on normal melanocytes (On coge ne Res., 1: 357-374, 1987). Therefore, human tumor antigens are in most cases not truly tumor-specific antigens, but rather they are self-antigens expressed in some normal cells and tissues.
- cancer vaccine therapy that activates cytotoxic T cells in the body of cancer patients by administering tumor antigen peptides is being developed.Melanoma-specific tumor antigens have been reported in clinical trials. Have been. For example, subcutaneous administration of melanoma antigen gp100 peptide to melanoma patients and intravenous injection of interleukin-12 (1 L-2) resulted in tumor shrinkage in 42% of patients. (Nature Medicine, 4: 321, 1998). Thus, by using tumor antigens as vaccines, an effective cancer therapeutic effect can be expected.
- the lck gene which encodes the p56 lck protein, one of the src family membrane tyrosine kinases, has an essential function in T cell development and function.
- the present invention finds and provides a novel tumor antigen having recognition by cytotoxic T cells, which is useful for specific immunotherapy of patients with adenocarcinoma and epithelial cancer, for example, colon cancer and lung cancer.
- the purpose is to:
- a peptide having recognition ability by HL AA 2402-restricted or HLA-A2-restricted cytotoxic T cells a polynucleotide encoding the peptide or a complementary strand thereof, containing the polynucleotide Recombinant vector, transformant containing the recombinant vector, method for producing the peptide, antibody against the peptide, compound interacting therewith, screening method thereof, pharmaceutical composition utilizing these, and use of these
- the purpose of the present invention is to provide a diagnostic means.
- HLA-A2402-restricted tumor-specific cytotoxic T cells K E4-CTL, which are activated by recognizing HLA-A24 and a tumor antigen peptide
- HLA — HLA that is activated by recognizing A2 and tumor antigen peptide— OK—CTL and GK—CTL which are A2-restricted tumor-specific cytotoxic T cells.
- a tumor antigen capable of activating cytotoxic T cells was identified from the cDNA library of the KE tumor cell line using the gene expression cloning method (Gene Expression Cloning Method) and further restricted to HLA-A2402.
- Z or HLA-A2-restricted cytotoxic T cells have been found to have peptides having the ebitope of the tumor antigen recognized by the present invention, thereby completing the present invention.
- SEQ ID NO: 1 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12 , SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, Or a peptide consisting of the amino acid sequence of SEQ ID NO: 17,
- Xbb is Tyr or Phe
- Xcc is Leu or Ile
- Xdd is Arg or Ghi
- Xee is Ser or Ala
- Xff is Val or Phe
- Xgg is Glu or Asp
- Xhh is Phe or Tyr
- Xii is Phe or Tyr
- a cytotoxic T cell inducer comprising at least the peptide of (1) or (2)
- a cancer vaccine comprising at least the peptide of (1) or (2),
- (11) an antibody that immunologically recognizes the peptide of (1) or (2), (12) Interaction with the peptide of (1) or (2) above to enhance recognition by at least HLA-A2402-restricted and / or HLA-A2-restricted cytotoxic T cells.
- a pharmaceutical composition for treating cancer comprising at least one of the antibody of 1) or the compound of (13), which comprises an effective amount for treating cancer.
- a therapeutic method comprising using the cytotoxic T cell inducer of (3), the cancer vaccine of (5), or the pharmaceutical composition of (14) for a cancer disease.
- a reagent kit used in the method of the above (16), wherein at least the peptide of the above (1) or (2), the polynucleotide of the above (6) or (7), the antibody of the above (11) A reagent kit comprising at least one of the following:
- Figure 1 HLA-A24-restricted cytotoxicity by recognizing the 1ck gene product It is a figure that shows that harmful T cells (KE4-CTL) are activated to produce inferon ferrona (IFN-a).
- KE4-CTL harmful T cells
- IFN-a inferon ferrona
- FIG. 2 HLA-A2-restricted cytotoxic T cells are activated to produce interferon (IFN-a) by recognizing the 1ck gene product.
- A), (B) and (C) represent HLA—A2-restricted CTLs, respectively—OK—CTL-e substrain, GK—CTL 2—2—4 substrain and GK—CTL L 2—2—5 The results obtained when the sub-strain was used are shown.
- FIG. 3 shows the amount of IFN- ⁇ production from KE—CTL stimulated by C 1R / A 2402 cells transfected with Lck-derived peptides.
- FIG. 4 LCK-derived peptide activates KE-CTL in a concentration-dependent manner.
- FIG. 5 shows the results of confirming the cell phenotype (phenot ype) and MHC restriction of KE-CTL by performing peptide recognition by KE-CTL in the presence of various antibodies.
- (A), (B) and (C) show the results when Lck208-216, Lck486-494 and Lck488-497 were used as Lck-derived peptides, respectively.
- Figure 6 Drawing showing differences in peptide recognition of £ 4- (subline) (A), (B), (C) and (D) are sub-lines # 19, respectively. Shown are the results obtained using, substrain # 49, substrain # 93, and clone # 80.
- FIG. 3 is a view showing the results of a study using (HLA-A24 +) and COLO201 (HLA-A24 ") as target cells using IFN- ⁇ production from CTL as an index.
- FIG. 8 shows the results of examining the cytotoxic activity of CTLs induced by Lck-derived peptides on various tumor cells by 51 Cr release test.
- (A) and (B) represent Lck488-497 and Lck20 as the peptides, respectively. The results using 8—216 are shown.
- FIG. 9 Peptide-derived CTLs derived from peripheral blood mononuclear cells (PBMC) of colorectal cancer patients show specificity for the peptides.
- A), (B), (C) and (D) show that when peptides were not used for prestimulation of PBMC in cancer patients, Lck208-216, Lck486-494, And Lck488-497 results are shown.
- Fig. 10 Induction of CTLs by peptide from peripheral blood mononuclear cells (PBMC) of colorectal cancer patients in the presence of various antibodies, confirming the induced CTL cell phenotype (phenotype) and MHC restriction It is a figure which shows the result.
- PBMC peripheral blood mononuclear cells
- Fig. 11 is a graph showing the frequency of peptide-induced CTL progenitor cells in peripheral blood mononuclear cells (PBMC) of colorectal cancer patients.
- the horizontal axis represents the number of added CTLs per 1 ⁇ l
- the vertical axis represents the growth negative fraction (fraction neat ive cu 1 ture).
- FIG. 12 shows the activation of KE4-CTL by a peptide derived from Src family.
- FIG. 13 HLA of a peptide derived from L CK-82 restriction II! "] ⁇ Shows the results of analysis of the activation ability, (A) shows the results obtained when the OK-CTL strain was used as HLA-A2-restricted CTL, and (B) shows the results obtained using GK-CTL2--2. — Shows the results when using 4 sub-strains.
- FIG. 14 Lck-derived peptide activates HLA-A2-restricted CTL in a concentration-dependent manner.
- A (A), (B) and (C) used OK—CTL-e substrain, GK—CTL L2—2—4 substrain, and GK—CTL2—2_5 substrain as CTL The result of the above is shown.
- FIG. 2 shows that A2-restricted cytotoxic T cells can be induced.
- A) and B) show the results of examining the induction of CTLs from PBMCs derived from colorectal cancer patient example 1 using the production of IFN- ⁇ as an index and the results confirmed by a cytotoxicity test.
- C) and (D) show the results of a similar study of the induction of CTLs from PBMCs from colorectal cancer patient example 2.
- HLA-A24 which is a type of HLA-A molecule found in many Japanese people, and recognized HLA-A24 and a tumor antigen peptide to activate HLA-A24.
- a 2402-restricted tumor-specific cytotoxic T cells (KE4-CTL) were established from esophageal cancer patients (Int. J. Cancer, 81: 4591-466, 1999). Using this cytotoxic T cell as an effector, a tumor antigen capable of activating this cell was identified from a cDNA library of the KE tumor cell line using the gene expression cloning method.
- Activation of cytotoxic T cells can be determined using the enzyme immunosorbent assay (ELISA) kit and interferon-er (IFN-a) produced from the cytotoxic T cells. It was performed by measuring. As a result, one cDNA clone was recognized by HLA-A24-restricted KE4-CTL and activated the KE4-CTL (see Fig. 1), and the nucleotide sequence of this cDNA clone was 1,750 bases. (Bp) long and: It was found to have 100% homology with position 283-2,032 in the nucleotide sequence of the Lck gene. The nucleotide sequence of the 1 ck gene at this position corresponds to the amino acid sequence at positions 31 to 506 containing the majority of the L ck protein consisting of 509 amino acids.
- ELISA enzyme immunosorbent assay
- IFN-a interferon-er
- the Lck protein is a tumor antigen capable of activating not only HLA-A24-restricted CTL but also HLA-A2-restricted CTL.
- HLA-A24-restricted CTL HLA- A0207
- CTL lines GK- CTL2- 2- 4 established from lung cancer patients
- HLA-AO206 HLA-AO206
- the lck gene encodes a tumor antigen ebitope recognized by HLA-A24-restricted or HLA-A2-restricted tumor-specific cytotoxic T cells.
- L ck (56 kD and 59 kD) at the protein level in various cells and tissues was examined by Western blot analysis using anti-L CK monoclonal antibodies.
- the Lck protein is found in all malignant tumor cell lines tested, such as squamous cell carcinoma (SCC) or adenocarcinoma cell line, as well as in esophageal cancer, lung SCC and lung adenocarcinoma cells. It was detected in the majority of fresh tumor tissues from various organs. In particular, Lck protein was highly expressed in colon, lung, and esophageal cancer tissues. On the other hand, none was detected in any of the non-neoplastic colon tissues. The Lck protein was not detected in unstimulated peripheral blood mononuclear cells (PBMC), but was activated after stimulation with 10 g / m1 of phyt ohemagglutinin (PHA) for 48 hours. It was detected in the cytoplasmic fraction of PBMC (PHA-blast). (A peptide that can activate HL AA 2402 restricted CTL)
- PBMC peripheral blood mononuclear cells
- the selection of a tumor antigen peptide capable of activating cytotoxic T cells from the 13 peptides was performed by measuring IFN- ⁇ produced by CTL as an indicator of its CTL activating action.
- Lck 208-216 SEQ ID NO: 3
- Lck486-494 SEQ ID NO: 1
- Lck488-497 SEQ ID NO: 2
- the CTL activating ability of Lck486-494 (SEQ ID NO: 1) or Lck488-497 was concentration-dependent, and was observed at about 1 nM.
- the activity of Lck208-216 was observed at 100 nM or more (see FIG. 4).
- KE4-CTL Activation of KE4-CTL by these three peptides was inhibited by anti-CD3, anti-CD8 and anti-MHC class I monoclonal antibodies, but not by anti-CD4, anti-MHC class II and anti-CD13 monoclonal antibodies. It was not inhibited by the antibody. Therefore, KE4-CTL was found to have a CD3 +, CD8 +, CD4- cell phenotype.
- HLA-A24-restricted KE Threee peptides that activate CTL in a concentration-dependent manner (Lck208—216 (SEQ ID NO: 3), Lck486-494 (SEQ ID NO: 1), Lck488-497 (SEQ ID NO: 2) )] Also, peripheral blood mononuclear cells obtained from colorectal cancer patients HLA-A24 restricted CTLs against Lck expressing tumor cell lines (KE4, SW620 and COLO 201) were induced from spheres (PBMC).
- PBMC peripheral blood mononuclear cells obtained from colorectal cancer patients HLA-A24 restricted CTLs against Lck expressing tumor cell lines
- Lck208-216 SEQ ID NO: 3
- Lck486-494 SEQ ID NO: 1
- Lck488-497 SEQ ID NO: 2
- Stimulated PBMC produced more IFN- ⁇ in response to HLA-A24 + tumor cells (KE4 and SW 620) than to HLA-A24-tumor cells (C0LO201).
- PBMC stimulated with these three Lck-derived peptides lysed (1 sis) HLA-A24 + KE and SW620 tumor cells, but HLA-A24 + PHA-activated T cells obtained from healthy individuals. None of the cells or HLA—A24—C0L0201 tumor cells lysed.
- the peptide derived from Lck was able to induce HLA-A24-restricted tumor-specific cytotoxic T cells in PBMC of colorectal cancer patients.
- Lck-derived peptides failed to induce HLA-A24-restricted CTL activity against tumor cells in healthy human PBMCs. From these results, it is considered that T cells in peripheral blood of a healthy subject are immunologically tolerant to Lck.
- L c of the present invention k-peptide can induce CTLs in PBMC of colorectal cancer patients.
- Peptides are also included in the peptides of the present invention.
- Xbb is Tyr or Phe
- Xcc is Leu or Ile
- Xdd is Arg or Gln
- Xee is Ser or Ala
- Xff is Val or Phe
- Xgg is Glu or Asp
- Xhh is Phe or Tyr
- Xii is Phe or Tyr
- the peptide derived from the Src family was able to induce HLA-A24-restricted cytotoxic T cells from PBMC obtained from a cancer patient. That is, PBMC obtained from a cancer patient stimulated with a peptide derived from the Src family reacted with KE4 cells and SW620 cells to produce IFN- ⁇ .
- L ck486—494 (SEQ ID NO: 1) was found in 4 of 7 cancer patients, S rc 51 1—519 (SEQ ID NO: 4) was found in 2 of 3 patients, and Y es 508—516 (SEQ ID NO: 5) was found in 3 In 1 case, Fyn 5 12-520 (SEQ ID NO: 6) was 1 in 2 cases, Hck 503—511 (SEQ ID NO: 8) was 2 in 2 cases, and Blk 482—490 (SEQ ID NO: 9) was in 2 cases In one of the two cases, the production of IFN- ⁇ from PBMC was induced.
- the three Lck peptides and peptides derived from Src families of the present invention can induce HLA-A24-restricted tumor-specific cytotoxic T cells in PBMC of colorectal cancer patients. Therefore, the peptide of the present invention can be used for an agent and method for inducing tumor-specific cytotoxic T cells. Lck is also used for colon, lung and And in most cancer tissues, including the esophagus. HLA—A24 allele (al 1 e 1 e) accounts for about 60% of the Japanese population (often 95% of the genotype is A2402), 20% of the Caucasus, and Africans 1: 106 5 to 1220, Oxford: Oxford Science Public at ions, 1992). Therefore, the peptides of the present invention can be applied to specific immunotherapy in a relatively large number of cancer patients.
- L ck 61-69 SEQ ID NO: 11
- L ck 246-254 SEQ ID NO: 12
- L ck 422-430 SEQ ID NO: 16 was concentration-dependent [Fig. 14 (A), (B) and (C)].
- PBMCs of colorectal cancer patients with metastases were stimulated three times in vitro with any of these three peptides, and then irradiated to autologous PBMCs (autologous-PBMCs).
- autologous-PBMCs When stimulated with peptide-pulsed cells as antigen presenting cells (APC), PBMC of the colorectal cancer patient stimulated with Lck246-254 (SEQ ID NO: 12) and Lck422-430 (SEQ ID NO: 16) did not respond to the HLA-A2_ colorectal cancer cell line COLO 320, but responded to the HLA-A2 + colorectal cancer cell line SW 620 or the HLA-A2 + pancreatic cancer cell line Panc-11. It produced IFN- ⁇ [see FIGS. 15 (A) and (C)] and lysed HLA-A2 + tumor cells [see FIGS. 15 (B) and (D)].
- Lck246-254 SEQ ID NO: 12
- Lck422-430 SEQ ID NO: 16
- Induction of HLA-A2-restricted CTL was measured using IFN- ⁇ production against HLA-A2 + colon cancer cell line SW620 as an index.
- Lck 246-254 SEQ ID NO: 12
- these three peptides can be used for an agent and a method for inducing cytotoxic T cells.
- the HLA-A2 allele (al lele) accounts for about 40% of the Japanese population, 49% of North Koreans, 38% of Southern Caucasians, 23% of Africans, and 53% of Chinese ( HLA 199 1, Vol. 1: 1065 ⁇ ; L22 0, Oxford: Found in Oxford sci- ent Scientific Public ions, 1992). Therefore, these peptides can be applied to specific immunotherapy in a relatively large number of cancer patients. (peptide)
- the peptide of the present invention is a peptide having the amino acid sequence described in SEQ ID NO: 1 to 9 or SEQ ID NO: 11 to 17 in the sequence listing.
- the peptide of the present invention can induce or activate HLA-A24-restricted or HLA-A2-restricted cytotoxic T cells.
- the peptide of the present invention is a peptide consisting of the amino acid sequence shown in SEQ ID NO: 10 in the sequence listing, and is a peptide capable of inducing and / or activating at least HLA-A24-restricted cytotoxic T cells. It is possible. The selection of peptides capable of inducing and / or activating HLA-A24-restricted cytotoxic T cells can be performed using the method described in Examples described later.
- the peptide of the present invention may be a peptide capable of inducing and / or activating both 111 ⁇ -24-restricted ( ⁇ 1] ⁇ and 111 ⁇ 8.2-restricted CTL.
- HLA-A2402 binding and Z or HLA-A2-restricted cytotoxic T cells can be used as an index to indicate the degree of recognition.
- a peptide comprising an amino acid sequence having mutations such as deletion, substitution, or addition of several amino acids or induced mutations. Means for introducing mutations such as deletions, substitutions, and additions or induced mutations are known per se, and use, for example, the technique of Ulmer (Ulmer, L.M., Science, 219, 666, 1983). I can do it.
- these usable peptides can be modified to such an extent that the function is not significantly changed, such as by modifying the constituent amino group or carboxyl group.
- proteins encoded by the 1ck gene have slightly different amino acid sequences presumed to be based on polymorphisms (Nature, 319: 682-685, 1986, Eur. J. Immunol 1., 16: 1643-1646, 1986, J. Cell. Biochem., 38: 117-126, 1988, Gene, 84: 105— 113, 1989).
- the peptides of the present invention also include peptides derived from 1 ck gene products having different amino sequences and capable of inducing HLA-A24-restricted and / or HLA-A2-restricted CTLs.
- one of the peptides of the present invention comprises the amino acid sequence DY LRSVLEDF described in SEQ ID NO: 2 in the sequence listing, and is reported in Nature, 319: 682-685, 1986.
- the amino acid sequence at positions 488-497 based on the amino acid sequence of the Lck protein is DYLRSVLDDF, and this sequence is also included in the HLA-A24 binding motif.
- the peptide of the present invention is a tumor antigen peptide capable of inducing and Z or activating HLA-A24-restricted and / or HLA-A2-restricted CTL, Can be used to induce and / or activate CTL. That is, the peptide of the present invention can be used for cancer specific immunotherapy such as a cancer vaccine.
- the polynucleotide of the present invention and the complementary chain thereof include the peptides of SEQ ID NOS: 1 to 9 and SEQ ID NOs: 11 to 17, and the deletion, substitution, addition, etc.
- the polynucleotide of the present invention also includes a polynucleotide that hybridizes to these polynucleotides under stringent conditions.
- a DNA molecule under stringent conditions The "DNA molecule that hybridizes” can be obtained, for example, by the method described in the aforementioned Moe ecu el er Cloning.
- hybridize under stringent conditions means, for example, heating at 42 ° C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, followed by This shows that a positive hybridizing signal is still observed under the conditions of washing at 68 ° C. in a solution of l ⁇ SSC and 0.5% SDS.
- polynucleotides of the present invention all provide useful genetic information for the production of the peptides of the present invention, or can be used as reagents and standard products as nucleic acids.
- the peptide of the present invention can be provided by a gene recombination technique using a host known per se such as Escherichia coli, yeast, Bacillus subtilis, insect cells, animal cells, and retroviruses.
- a host known per se such as Escherichia coli, yeast, Bacillus subtilis, insect cells, animal cells, and retroviruses.
- the peptide of the present invention has been confirmed to be recognizable by cytotoxic T cells in the form of a simple protein, and the presence or absence of sugar addition to the protein can be ignored. It can be easily done by considering only productivity.
- Transformation is performed by a known method.
- a host is transformed using a plasmid, chromosome, virus, or the like as a lebricon.
- a more preferable system there is an integration method into a chromosome in consideration of the stability of the gene, but an autonomous replication system using an extranuclear gene can be used simply.
- the vector is selected according to the type of the selected host, and includes a gene sequence to be expressed and a gene sequence carrying information on replication and control as components. Combinations are classified by prokaryotic cells and eukaryotic cells, and promoters, ribosome binding sites, terminators, signal sequences, enhancers, and the like can be used in combination by a method known per se.
- the transformant is cultured under conditions suitable for the culture conditions of each host known per se. Culture depends on the biological activity of the expressed and produced peptides, especially on cytotoxic T cells. Although it may be performed using recognizability as an index, it is produced by subculture or batch culture using the amount of transformant in the medium as an index.
- the peptide of the present invention can also be produced by a method known in ordinary peptide chemistry.
- a peptide synthesis (Maruzen) 1975, "Peptide Synthesises, Intelscience, New York 1996” is exemplified, but of course, known methods are widely available. (Recovery of peptide)
- the peptide of the present invention can be recovered by using a combination of molecular sieve, ion column chromatography, affinity chromatography, etc., or using ammonium sulfate, alcohol, etc. based on the difference in solubility, using the recognition by cytotoxic T cells as an index. Purification and recovery can also be performed by fractionation means. More preferably, a method of preparing an antibody against the peptide and specifically adsorbing and collecting the antibody with a polyclonal antibody or a monoclonal antibody is used. (Antibody)
- An antibody that immunologically recognizes the peptide of the present invention can be obtained according to a method for producing an antibody known per se. For example, it can be obtained by administering the peptide of the present invention to an animal in the presence or absence of an adjuvant, alone or in combination with a carrier, and inducing immunity such as a humoral response and / or a cellular response.
- the carrier is not particularly limited as long as it does not cause harmful effects on the host itself, and examples thereof include cellulose, polymerized amino acid, albumin and the like.
- mice, rats, rabbits, goats, horses and the like are preferably used.
- the polyclonal antibody can be obtained from the serum of an animal immunized with the peptide of the present invention by an antibody recovery method known per se, for example, immunoaffinity mouth chromatography as a preferable means.
- antibody-producing cells are recovered from an animal to which the above-mentioned immunization means have been applied, and a known means for transforming permanently proliferating cells is introduced.
- the polyclonal antibody or monoclonal antibody thus obtained can be used as an antibody for purification of the peptide of the present invention, a reagent, a labeling reagent, or the like.
- the peptide of the present invention a polynucleotide encoding the peptide and its complementary chain, cells transformed based on the amino acid sequence and base sequence information thereof, or an antibody that immunologically recognizes the peptide of the present invention include:
- the present invention provides an effective means for screening a compound capable of inducing or activating a cytotoxic T cell, alone or in combination.
- the screening method can be constructed using a drug screening system known per se.
- the present invention is also directed to compounds obtained by the screening method of the present invention.
- the compound is a compound that enhances the HLA-A2402-restricted and / or HLA-A2-restricted CTL recognition of the peptide of the present invention, and interacts with the polynucleotide of the present invention to express the same.
- a peptide of the present invention a polynucleotide encoding the peptide and its complementary chain, a vector prepared based on the amino acid sequence and base sequence information thereof, a cell transformed with the vector, and a peptide of the present invention immunologically.
- Compounds that enhance the recognition of HLA-A2402-restricted and / or HLA-A2-restricted CTLs of the peptides of the present invention obtained by the screening method of the present invention.
- Interaction with the polynucleotide of the invention to enhance its expression A compound or the like is used alone or in combination of two or more to provide a pharmaceutical composition comprising at least one of them.
- the pharmaceutical composition of the present invention is useful in treating cancer.
- a pharmaceutical composition containing the peptide of the present invention is used as a so-called cancer vaccine.
- the peptide of the present invention is used alone or bound to a carrier in the presence or absence of an appropriate adjuvant to activate cellular immunity.
- the carrier is not particularly limited as long as it does not cause harmful effects on the human body, and examples thereof include cellulose, polymerized amino acids, and albumin.
- the dosage form can be appropriately selected by applying means of a peptide preparation known per se. The dose varies depending on the recognition by cytotoxic T cells, but is generally 0.1 mg to 100 mg / day / adult human, preferably 0.1 mg to 10 mg as an active substance. mg / day / adult Human. It is given once every few days or months.
- the method is also effective by collecting a mononuclear cell fraction from the peripheral blood of a patient, culturing the mononuclear cell fraction with the peptide of the present invention, and returning the mononuclear cell fraction in which CTL is induced to the blood of the patient. It is possible to obtain a novel cancer vaccine effect. Culture conditions such as mononuclear cell concentration and peptide concentration during culture can be determined by simple experiments. At the time of culturing, a substance having lymphocyte proliferation ability, such as quinone leukin 2, may be added.
- the polynucleotide encoding the peptide of the present invention and its complementary strand are useful for gene therapy of cancer.
- the amount of the polypeptide encoding the peptide of the present invention is from 0.1 to 100 mg / day / adult human, preferably Is lg to 50 mg gZ days / adult human. It is given once every few days or months. (Diagnosis method and diagnostic reagent kit)
- the peptide of the present invention is useful as a diagnostic method for diseases associated with the expression of the peptide (particularly gastrointestinal cancer).
- the peptide of the present invention can be used for its interaction and reactivity with a nucleic acid sequence encoding the peptide.
- a nucleic acid sequence encoding the peptide.
- the measurement may be carried out using a known antigen-antibody reaction system, enzyme reaction system, PCR reaction system, or the like.
- the present invention also includes a reagent kit used for the diagnostic method.
- the reagent kit of the present invention comprises at least one of the peptide of the present invention, a polynucleotide encoding the peptide, and an antibody recognizing the peptide.
- a tumor antigen capable of activating cytotoxic T cells stimulates the transflector Ekushi Yong were VA 13 cells KE 4 tumor cells the c DNA library total of 10 5 cDNA clones prepared from with HLA-A 2402 The cells were used as cells (stimul ator) and cultured with CTL to obtain cDNA clones that activate CTL. The activation of CTL was measured using IFN- ⁇ production as an index. By this method, it is possible to identify a gene encoding a tumor rejection antigen (J. Exp. Med. 187: 277-288, 1998).
- the CTL used as effector cells is HLA-A2402 restricted tumor-specific cytotoxic T cells (KE4-CTL).
- KE4-CTL HLA-A2402 restricted tumor-specific cytotoxic T cells
- This cell is the esophagus Established from cancer patients (Int. J. Cancer, 81: 457-466, 1999).
- the poly (A) + RNA was converted to cDNA using KE4 tumor cells, and this was ligated to the Sail adapter to express the expression vector -pSV-SPOT-1 (GIBC 0 BL).
- HLA-A2 402 or control HL A-AO201. 08 was obtained by reverse transcription PCR (RT-PCR) and cloned into eukaryotic expression vector pCR3 (Invitrogen).
- clone 21 was found to activate HLA-A24-restricted KE4-CTL (Fig. 1).
- the nucleotide sequence of this cDNA clone is 1,750 bases (bp) in length, and the position of the nucleotide sequence corresponding to positions 31-506 of the Lck protein amino acid sequence consisting of 509 amino acids is position 283-2,032. And 100% homology. That is, it was suggested that the protein encoded by the Lck gene is a tumor antigen that can activate CTLs in an HLA-A2402-restricted manner.
- HLA-A2402-restricted KE-CTL HLA-A0207
- HLA-A0207 0K-CTL-e substrain
- OK-CTL a sub-strain of the CTL strain
- GK-CTL two sub-strains of G, CTL
- K-CTL2-2-4 substrain (HLA-A0206) and GK-CTL2-2-5 substrain (HLA-A0206) total 3 HLA-A2-restricted CTLs as one effector cell VA13 cells transfected with the 1 ck gene and HLA-A0201, HLA-AO206, HLA-A0207, HLA-A2402, or HLA-A2601 was used as a stimulator cell, and Lck protein was found to be a tumor antigen capable of activating not only 11-828-restricted CTL but also 11-82-restricted ⁇ 11 ⁇ (Fig. 2 (A), (B) and (C)].
- L ck (56 kD and 59 kD) at the protein level in various cells and tissues was examined by Western blot analysis using an anti-L CK monoclonal antibody.
- esophageal cancer cells used.
- colorectal cancer cell lines (COLO 201, COLO 205, COLO 320, HCT 116, and SW 620)
- lung cancer cell lines (LK87: adenocarcinoma cells, and LK79: small cell carcinoma cells)
- KE 4 An esophageal cancer cell line
- Samples were 1 OmM Tris—HC1, H7.4, 150 mM NaCl, 0.5 Triton X-100, 0.2 mM PMS F (Sigma Chemical Co.) And 0.03 units of trypsin inhibitor, dissolved in a buffer consisting of 1 unit of aprotinin, sonicated, and centrifuged at 14, OOO rpm for 20 minutes. The obtained supernatant was used as a cytoplasmic (cytoso1) fraction. Lysates were separated by 10% SDS-PAGE.
- the protein obtained in the acrylamide gel was transferred (blotted) to Hybond TM —polyvinylidine difluoride membrane (Amersham), and reacted with an anti-Lck monoclonal antibody (Santa Cruz) at room temperature. Time was spent. Other methods followed Western blot analysis as previously reported (Int. J. Cancer, 54: 158-165, 1995).
- Lck protein was not detected in unstimulated peripheral blood mononuclear cells (PBMC), but was activated after stimulation with 10 // g / ml of phyt ohemagglutinin (PHA) for 48 hours.
- PBMC peripheral blood mononuclear cells
- PHA phyt ohemagglutinin
- cytoso 1 cytosolic fraction.
- the Lck protein is present in all malignant tumor cell lines tested, such as SCC or adenocarcinoma cell lines, as well as in fresh tumor tissue from a variety of organs, such as esophageal cancer, lung SCC, and lung adenocarcinoma cells. Detected in large numbers. On the other hand, none was detected in any of the non-neoplastic colon tissues (Table 1).
- Ovarian cancer 0/12 ND Hepatocellular carcinoma 0/13 ND Osteosarcoma 0/16 ND Primary brain tumor 0/16 5/24
- Lck-derived peptide capable of binding to HLA-A2402 molecule is HLA-A
- 6 peptides (Lck 71-80, Lck 208-216 (SEQ ID NO: 3), Lck317-325, Lck353-36 l, Lck486-494 (SEQ ID NO: 1) , Lck488-497 (SEQ ID NO: 2)] has the activity of enhancing IFN-a production in CTLs (FIG. 3), and in particular, has three peptides [Lck208-216 (SEQ ID NO: 3), Lck 486-494 (SEQ ID NO: 1) and Lck488-497 (SEQ ID NO: 2)].
- Lck486-494 SEQ ID NO: 1
- Lck488-497 SEQ ID NO: 2
- peptide to enhance IFN- ⁇ production by CTL was concentration-dependent, and was observed at about 1 nM.
- the activity of Lck208-216 was observed at 100 nM or more (FIG. 4).
- KE4-CTL has the CD3 + CD8 + CD4-phenotype, The cells were confirmed to be cytotoxic T cells that recognize MHC class I. Furthermore, in order to confirm the specificity of the peptide in CTL, a sub-strain of KE4-CTL was isolated from a parental strain, HLA-A2402-restricted KE4-CTL, by limiting dilution culture.
- Lck protein from three peptides [(Lck208-216 (SEQ ID NO: 3), Lck486-494 (SEQ ID NO: 1), Lck488-497 (SEQ ID NO: 2)]) from PBMC obtained from a colon cancer patient
- Lck208-216 SEQ ID NO: 3
- Lck486-494 SEQ ID NO: 1
- Lck488-497 SEQ ID NO: 2
- the dendritic cells were isolated from PBMC in RPMI 1640 (GIBCO BRL) containing 10% FCS, 100 UZm 1 of IL-14 and 100 U / ml of GM-CSF (granulocyte macrophage-colony stimulating factor). (2 x 10 6 cells / well) by incubating for 7 days.
- FIG. 7 shows the results.
- PBMCs obtained from healthy humans were stimulated with any of the three peptides pulsed using irradiated PBMCs as antigen-presenting cells (APCs). Did not show.
- PBMC obtained from healthy subjects showed HLA-A24-restricted CTL activity when stimulated with peptide-pulsed dendritic cells (Dendritic Ce11; DC) as APC (Table 3). ).
- Lck488-497 90 140 6 for a 51 Cr release test from target cells, the above-mentioned PBMCs stimulated three times with peptides were irradiated with HLA-A24 which had been previously pulsed with the corresponding peptides. The cells were further cultured with a single feeder cell consisting of + heterologous PBMC (2 ⁇ 10 5 cells). Approximately 24 days after reculturing, the cytotoxic T cell activity of these cells was confirmed by measuring the amount of IFN- ⁇ production, and these cells were subjected to a 6-hour 51 Cr release test using an effector / target (target cell). The cytotoxicity was examined directly by changing the ratio of).
- Lck208-216 SEQ ID NO: 3
- Lck4886-494 SEQ ID NO: 1
- Lck4888-497 SEQ ID NO: 2
- the activity of inducing HLA-A24-restricted CTLs against tumor cell lines KE4, SW620 and COLO201
- the measurement was performed using the IFN-a production amount as an index.
- the method of inducing CTL and the method of measuring IFN- were the same as those in Example 4.
- SW620 cells were used as target cells, and anti-CD4 (NUTh / s), anti-CD8 (NuTC / i), anti-CD14, MHC class I (W6 / 32) or anti-MHC class II (HDR 1) antibodies were added at 10 Adg / ml and Lck488-497 (SEQ ID NO: 2) at lO ⁇ g / ml, respectively, and induced from the above colorectal cancer patients The added CTL was added, incubated, and the amount of IFN- ⁇ produced in the supernatant was measured (FIG. 10).
- CTLs derived from colorectal cancer patients were cytotoxic T cells having a CD8 + CD4-phenotype and recognizing MHC class I.
- the CTL precursor cells in PBMC of the above colorectal cancer patients were examined.
- SW 620 cells were seeded on a 96-well plate, incubated, and the CTL of the above colon cancer patient, which had been previously stimulated with Lck488-497 (SEQ ID NO: 2), was added at 1 to 100 cells / well, and further added. After culturing, the survival of SW620 cells as target cells was confirmed.
- C of the above colon cancer patient not stimulated with peptide TL was used as a control. The results are shown in FIG.
- the frequency of CTL precursor cells in PBMC of colorectal cancer patients is 1/634 when not stimulated with the peptide, but becomes 1/81 when stimulated with Lck488-497 (SEQ ID NO: 2). That is, it was confirmed that stimulation with the peptide increased the number of CTL precursor cells.
- L recognizes as a tumor antigen epitope, and that this site contained in the kinase domain in the Lck protein has significance for tumor rejection. Focusing on this amino acid sequence DY LRSV and searching for peptides having homology to this sequence, as shown in Table 5, tyrosine kinases belonging to the same Src family as Lck (Ann. Rev. Biochem. 54: 897-930, 1985) found that some have homologous amino acid sequences.
- Hck 503-515 ⁇ F E Y 1 Q s V then D D F Y
- Example 7 CTL cells were added and cultured, and CTL inducing activity was examined using the amount of IFN- ⁇ produced in the culture supernatant as an index.
- KE4 was used as a target cell as a positive control.
- Other methods use the same method as in Example 4. Was.
- the peptides derived from each Src family showed the same or higher CTL-inducing ability than the Lck-derived peptides.
- L c k486 -494 (SEQ ID NO: 1: TFDYLRSVL), S rc 5 11-5 19 (SEQ ID NO: 4: TFEYLQAFL), Yes 508-5 16 (SEQ ID NO: 5: TFEY I QS FL), Fyn5 12- 520 (SEQ ID NO: 6: TFEYLQ SFL), Lyn489-497 (SEQ ID NO: 7: TFDYLQSVL), Hck503-511 (SEQ ID NO: 8: TFEYI QSVL), Blk482—490 (SEQ ID NO: 9: TFE FLQ SVL) was examined for its ability to induce HLA-A24 restricted CTL from PBMC obtained from metastatic cancer patients.
- the method of inducing CTLs and measuring the activity of CTLs were performed in the same manner as in Example 4.
- the target cells were KE4 cells (HLA-A2402 / 26), SW620 cells (HLA-A0201-NO24), and COLO201 cells. (HLA- ⁇ 010-0201) and ⁇ 13 cells (HLA-A02) were used.
- L c k486—494 (SEQ ID NO: 1) was found in 4 of 7 cancer patients, S rc 5 11 1—5 19 (SEQ ID NO: 4) was found in 2 of 3 patients, and Yes 508-5 16 (SEQ ID NO: 4) 5) is 1 in 3 cases, F yn 5 12—520 (SEQ ID NO: 6) is 1 in 2 cases, Hck 503—51 1 (SEQ ID NO: 8) is 2 in 2 cases, B 1 k 482 -490 (SEQ ID NO: 9) 81 ⁇ (induced (1 1 1 ⁇ in. However, Lyn489- 497 is CTL in both 2 cases discussed did not induce. EXAMPLE 8
- HLA tumor antigen peptide recognized by A2-restricted CTL
- the Lck-derived peptide capable of binding to two HLA-A molecules was searched for a peptide for the 111 ⁇ 8-82 binding motif (mo tif) and 24 different peptides were identified as 1ck gene products. (Nature, 319: 682-685, 1986). Tables 6 and 7 show the synthesized peptides.
- HLA HLA was obtained from PBMC obtained from various cancer patients.
- PBMC obtained from various cancer patients.
- SW620 cells HLA-A0201 / 24 Lck246-254 (SEQ ID NO: 12) induced CTL in PBMC in 2 of 6 cancer patients and Lck422-430 (SEQ ID NO: 16) in 3 of 6 patients (Table 1). 8).
- Table 8 Table 8
- the Lck-derived peptide and Src family-derived peptide of the present invention are tumor antigen peptides, and are HLA-A24 restricted and / or HLA-A2 restricted from PBMC of cancer patients. Tumor-specific cytotoxic T cells can be induced. Lck protein is expressed in most cancer tissues, including the colon, lung and esophagus. That is, the tumor antigen peptide of the present invention can be used for specific immunotherapy for cancer.
- the HL A-A24 allele (allele) accounts for about 60% of the Japanese population (often 95% of the genotype is A2402), 20% of the Caucasians, and of Africans. Found in 12%.
- the HLA-A2 allele is found in approximately 40% of Japanese, 53% of Chinese, 49% of North Americans, 38% of Southern Caucasians, and 23% of Black Africans. Therefore, the specific immunotherapy using the tumor antigen peptide of the present invention can be applied to a large number of cancer patients.
- the peptide provided by the present invention, the polynucleotide encoding the same, and the antibody recognizing the same provide extremely useful means in the field of cancer treatment and diagnosis.
- ⁇ 230> a peptide having the ability to induce HLA-24-restricted cytotoxic T cells prepared based on the amino acid sequence of Src family tyrosine kinase,
- Xaa can be Asp or Glu.
- Xaa can be Tyr or Phe.
- Xaa can be Asp or Glu.
- Xaa can be Tyr or Phe.
- Xaa can be Leu or lie.
- Xaa can be Arg or Gin. ⁇ 222> (7)
- Xaa can be Ser or Ala. ⁇ 222> (8)
- ⁇ 230> Xaa can be Val or Phe.
- ⁇ 222> (10) ⁇ 230> Xaa can be Glu or Asp.
- ⁇ 222> (12) 230> Xaa can be Phe or Tyr.
- Xaa can be Phe or Tyr.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001515830A JP4051602B2 (ja) | 1999-08-05 | 2000-08-03 | 腫瘍抗原 |
CA002381348A CA2381348C (en) | 1999-08-05 | 2000-08-03 | Lck-derived peptides activating ctls |
AU63183/00A AU6318300A (en) | 1999-08-05 | 2000-08-03 | Tumor antigen |
EP00949982A EP1207199B1 (en) | 1999-08-05 | 2000-08-03 | Tumor antigen |
DE60044193T DE60044193D1 (en) | 1999-08-05 | 2000-08-03 | Tumor antigen |
AT00949982T ATE464383T1 (de) | 1999-08-05 | 2000-08-03 | Tumor antigen |
US10/062,257 US7465452B2 (en) | 1999-08-05 | 2002-02-01 | Tumor antigen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/222101 | 1999-08-05 | ||
JP22210199 | 1999-08-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/062,257 Continuation-In-Part US7465452B2 (en) | 1999-08-05 | 2002-02-01 | Tumor antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001011044A1 true WO2001011044A1 (en) | 2001-02-15 |
Family
ID=16777163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/005220 WO2001011044A1 (en) | 1999-08-05 | 2000-08-03 | Tumor antigen |
Country Status (9)
Country | Link |
---|---|
US (1) | US7465452B2 (ja) |
EP (1) | EP1207199B1 (ja) |
JP (1) | JP4051602B2 (ja) |
AT (1) | ATE464383T1 (ja) |
AU (1) | AU6318300A (ja) |
CA (1) | CA2381348C (ja) |
DE (1) | DE60044193D1 (ja) |
ES (1) | ES2340357T3 (ja) |
WO (1) | WO2001011044A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011723A1 (ja) * | 2003-08-05 | 2005-02-10 | Green Peptide Co., Ltd. | 造血器腫瘍の予防および/または治療剤 |
WO2005073374A1 (ja) * | 2004-01-29 | 2005-08-11 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原蛋白質及びその利用 |
JP2007145715A (ja) * | 2003-12-08 | 2007-06-14 | Green Peptide Co Ltd | 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド |
WO2010021112A1 (en) * | 2008-08-19 | 2010-02-25 | Oncotherapy Science, Inc. | Hig2 and urlc10 epitope peptide and vaccines containing the same |
WO2012005161A1 (ja) | 2010-07-07 | 2012-01-12 | 株式会社グリーンペプタイド | がんペプチドワクチン |
JP5568309B2 (ja) * | 2007-09-18 | 2014-08-06 | 株式会社グリーンペプタイド | Ctl誘導剤組成物 |
WO2014136814A1 (ja) | 2013-03-08 | 2014-09-12 | 大鵬薬品工業株式会社 | 新規ctlエピトープ5連結ペプチド |
WO2014162962A1 (ja) * | 2013-04-01 | 2014-10-09 | 学校法人 久留米大学 | 腫瘍抗原ペプチド |
WO2015060235A1 (ja) * | 2013-10-21 | 2015-04-30 | 大鵬薬品工業株式会社 | 新規ctlエピトープ4連結ペプチド |
WO2019146588A1 (ja) * | 2018-01-23 | 2019-08-01 | 学校法人 久留米大学 | 抗Lck-486抗体およびこれを含むがん治療用組成物 |
WO2020004622A1 (ja) | 2018-06-29 | 2020-01-02 | 大鵬薬品工業株式会社 | 抗腫瘍剤及びその評価方法 |
WO2021132550A1 (ja) | 2019-12-26 | 2021-07-01 | 大鵬薬品工業株式会社 | 術後補助療法剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1430904A4 (en) * | 2001-08-29 | 2005-09-14 | Greenpeptide Co Ltd | desensitizing |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250431A (en) * | 1988-06-13 | 1993-10-05 | Dana-Farber Cancer Institute, Inc. | Alteration of the interaction of a T-cell receptor with a proteintyrosine kinase |
US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
US5962224A (en) * | 1995-12-19 | 1999-10-05 | Dana-Farber Cancer Institute | Isolated DNA encoding p62 polypeptides and uses therefor |
AU7228398A (en) * | 1997-04-11 | 1998-11-11 | John P. Robarts Research Institute, The | Lck serine phosphorylation assay for t-cell activation and activation-induced cell death |
US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
EP1430904A4 (en) | 2001-08-29 | 2005-09-14 | Greenpeptide Co Ltd | desensitizing |
WO2003037917A1 (fr) | 2001-10-30 | 2003-05-08 | Kyogo Itoh | Antigene de tumeur |
-
2000
- 2000-08-03 WO PCT/JP2000/005220 patent/WO2001011044A1/ja active Application Filing
- 2000-08-03 DE DE60044193T patent/DE60044193D1/de not_active Expired - Lifetime
- 2000-08-03 ES ES00949982T patent/ES2340357T3/es not_active Expired - Lifetime
- 2000-08-03 AU AU63183/00A patent/AU6318300A/en not_active Abandoned
- 2000-08-03 CA CA002381348A patent/CA2381348C/en not_active Expired - Lifetime
- 2000-08-03 JP JP2001515830A patent/JP4051602B2/ja not_active Expired - Lifetime
- 2000-08-03 EP EP00949982A patent/EP1207199B1/en not_active Expired - Lifetime
- 2000-08-03 AT AT00949982T patent/ATE464383T1/de not_active IP Right Cessation
-
2002
- 2002-02-01 US US10/062,257 patent/US7465452B2/en not_active Expired - Lifetime
Non-Patent Citations (10)
Title |
---|
"HLA", vol. L, 1991, OXFORD SCIENTIFIC PUBLICATIONS, pages: 1065 - 1220 |
EUR. J. IMMUNOL., vol. 16, 1986, pages 1643 - 1646 |
GENE, vol. 84, 1989, pages 105 - 113 |
J. CELL. BIOCHEM., vol. 38, 1988, pages 117 - 126 |
J. EXP. MED., vol. 187, 1998, pages 277 - 288 |
KIKUCHI M. ET AL.: "Identification of a SART-1-derived peptide of inducing HLA-A-A24-restricted and tumor-specific cytotoxic T", INT. J. CANCER, vol. 81, no. 3, May 1999 (1999-05-01), pages 459 - 466, XP002933334 * |
KOGA Y. ET AL.: "A human T-cell-specific cDNA clone(YT16) encodes a protein with extensive homology to a family of protein-tyrosine kinases", EUR. J. IMMUNOL., vol. 16, no. 12, 1986, pages 1643 - 1646, XP002933335 * |
NATURE, vol. 319, 1986, pages 682 - 685 |
See also references of EP1207199A4 |
TANAKA A. ET AL.: "DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes", MOL. CELL BIOL., vol. 7, no. 5, 1987, pages 1978 - 1983, XP002933336 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011723A1 (ja) * | 2003-08-05 | 2005-02-10 | Green Peptide Co., Ltd. | 造血器腫瘍の予防および/または治療剤 |
JP4579581B2 (ja) * | 2003-12-08 | 2010-11-10 | 株式会社グリーンペプタイド | 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド |
JP2007145715A (ja) * | 2003-12-08 | 2007-06-14 | Green Peptide Co Ltd | 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド |
WO2005073374A1 (ja) * | 2004-01-29 | 2005-08-11 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原蛋白質及びその利用 |
US9642900B2 (en) | 2007-09-18 | 2017-05-09 | Green Peptide Co., Ltd. | CTL inducer composition |
JP5568309B2 (ja) * | 2007-09-18 | 2014-08-06 | 株式会社グリーンペプタイド | Ctl誘導剤組成物 |
EP3494981A1 (en) | 2007-09-18 | 2019-06-12 | BrightPath Biotherapeutics Co., Ltd. | Ctl inducer composition |
EP2801367A1 (en) | 2007-09-18 | 2014-11-12 | Green Peptide Co., Ltd. | CTL inducer composition |
EP3156061A1 (en) | 2007-09-18 | 2017-04-19 | Green Peptide Co., Ltd. | Ctl inducer composition |
US9102715B2 (en) | 2007-09-18 | 2015-08-11 | Green Peptide Co., Ltd. | CTL inducer composition |
US20110243973A1 (en) * | 2008-08-19 | 2011-10-06 | Onotherapy Science Inc. | Hig2 and urlc10 epitope peptide and vaccines containing the same |
KR101713581B1 (ko) | 2008-08-19 | 2017-03-08 | 온코세라피 사이언스 가부시키가이샤 | Hig2 및 urlc10 에피토프 펩티드 및 이를 포함하는 백신 |
JP2012500184A (ja) * | 2008-08-19 | 2012-01-05 | オンコセラピー・サイエンス株式会社 | Hig2およびurlc10エピトープペプチドならびにそれを含むワクチン |
KR20110045052A (ko) * | 2008-08-19 | 2011-05-03 | 온코세라피 사이언스 가부시키가이샤 | Hig2 및 urlc10 에피토프 펩티드 및 이를 포함하는 백신 |
WO2010021112A1 (en) * | 2008-08-19 | 2010-02-25 | Oncotherapy Science, Inc. | Hig2 and urlc10 epitope peptide and vaccines containing the same |
CN102186491B (zh) * | 2008-08-19 | 2015-06-10 | 肿瘤疗法科学股份有限公司 | Hig2和urlc表位肽及包含它们的疫苗 |
US9119800B2 (en) * | 2008-08-19 | 2015-09-01 | Oncotherapy Science, Inc. | HIG2 and URLC10 epitope peptide and vaccines containing the same |
WO2012005161A1 (ja) | 2010-07-07 | 2012-01-12 | 株式会社グリーンペプタイド | がんペプチドワクチン |
WO2014136814A1 (ja) | 2013-03-08 | 2014-09-12 | 大鵬薬品工業株式会社 | 新規ctlエピトープ5連結ペプチド |
US9701729B2 (en) | 2013-03-08 | 2017-07-11 | Taiho Pharmaceutical Co., Ltd. | Peptide having 5 linked CTL epitopes |
WO2014162962A1 (ja) * | 2013-04-01 | 2014-10-09 | 学校法人 久留米大学 | 腫瘍抗原ペプチド |
JPWO2014162962A1 (ja) * | 2013-04-01 | 2017-02-16 | 学校法人 久留米大学 | 腫瘍抗原ペプチド |
JPWO2015060235A1 (ja) * | 2013-10-21 | 2017-03-09 | 大鵬薬品工業株式会社 | 新規ctlエピトープ4連結ペプチド |
WO2015060235A1 (ja) * | 2013-10-21 | 2015-04-30 | 大鵬薬品工業株式会社 | 新規ctlエピトープ4連結ペプチド |
US20160235828A1 (en) * | 2013-10-21 | 2016-08-18 | Taiho Pharmaceutical Co., Ltd. | Novel peptide having 4 linked ctl epitopes |
AU2014337643B2 (en) * | 2013-10-21 | 2017-07-13 | Taiho Pharmaceutical Co., Ltd. | Novel four-CTL epitope-joined peptide |
JP2017171678A (ja) * | 2013-10-21 | 2017-09-28 | 大鵬薬品工業株式会社 | 新規ctlエピトープ4連結ペプチド |
US10137183B2 (en) | 2013-10-21 | 2018-11-27 | Taiho Pharmaceutical Co., Ltd. | Peptide compositions having 4 linked CTL epitopes and uses thereof |
CN105658673A (zh) * | 2013-10-21 | 2016-06-08 | 大鹏药品工业株式会社 | 新型的具有4个连接的ctl表位的肽 |
CN105658673B (zh) * | 2013-10-21 | 2019-07-26 | 大鹏药品工业株式会社 | 新型的具有4个连接的ctl表位的肽 |
WO2019146588A1 (ja) * | 2018-01-23 | 2019-08-01 | 学校法人 久留米大学 | 抗Lck-486抗体およびこれを含むがん治療用組成物 |
WO2020004622A1 (ja) | 2018-06-29 | 2020-01-02 | 大鵬薬品工業株式会社 | 抗腫瘍剤及びその評価方法 |
WO2021132550A1 (ja) | 2019-12-26 | 2021-07-01 | 大鵬薬品工業株式会社 | 術後補助療法剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2381348A1 (en) | 2001-02-15 |
AU6318300A (en) | 2001-03-05 |
US7465452B2 (en) | 2008-12-16 |
EP1207199A1 (en) | 2002-05-22 |
EP1207199B1 (en) | 2010-04-14 |
EP1207199A4 (en) | 2002-11-27 |
ATE464383T1 (de) | 2010-04-15 |
CA2381348C (en) | 2009-10-06 |
ES2340357T3 (es) | 2010-06-02 |
DE60044193D1 (en) | 2010-05-27 |
US20020128201A1 (en) | 2002-09-12 |
JP4051602B2 (ja) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7404270B2 (en) | Tumor antigen | |
JP5182770B2 (ja) | Mhc分子を結合する腫瘍関連ペプチド | |
EP2470200B1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
TW200906850A (en) | TEM8 peptides and vaccines comprising the same | |
WO2001011044A1 (en) | Tumor antigen | |
US7078416B2 (en) | Polypeptides | |
AU2004267506A1 (en) | Anti-cancer vaccines | |
TWI627183B (zh) | 對於th1細胞之cdca1抗原決定位胜肽及含此之疫苗 | |
CN111793134A (zh) | 一种用于癌症治疗中的药物、肿瘤疫苗及抑制剂 | |
JP6255594B2 (ja) | Th1細胞のLY6Kエピトープペプチドおよびこれを含有するワクチン | |
US20050019341A1 (en) | Tumor antigen | |
JP2004000216A (ja) | 腫瘍抗原 | |
JP2001245675A (ja) | 腫瘍抗原 | |
JP4039483B2 (ja) | CD8+細胞傷害性Tリンパ球mHAエピトープペプチド及びその用途 | |
JP4925033B2 (ja) | ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド | |
TW201609801A (zh) | 來自vegfr2的胜肽及含其之疫苗 | |
JP2002507417A (ja) | Pap−1関連化合物 | |
JP2002360251A (ja) | Mn/ca9由来のhla−a24拘束性腫瘍抗原ペプチド | |
WO2001083689A2 (en) | PEPTIDES FROM FRAMESHIFT MUTATED DNA POLYMERASE δ GENE | |
JP2006129832A (ja) | CathepsinHタンパク質由来のCD8+細胞傷害性Tリンパ球mHAエピトープペプチド及びその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10062257 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2381348 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000949982 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000949982 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |